Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.75 |
| ▸ | ABHD6 | Q9BV23 | 10/20 | 0.58 |
| ▸ | MGLL | Q99685 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895230 | 0.86 | ESR1 (1.00) | ESR1ESR2ABHD6NPC1RAB9A | |
| SCHEMBL14781510 | 0.81 | ESR2 (0.67) | ESR1ESR2ABHD6MGLLNPC1 | |
| SCHEMBL13334504 | 0.81 | ESR1 (0.56) | ESR1ESR2ABHD6NPC1RAB9A | |
| SCHEMBL31164691 | 0.81 | ESR1 (0.90) | ESR1ESR2ABHD6NPC1RAB9A | |
| SCHEMBL21392851 | 0.80 | KMT2A (0.50) | ESR1ESR2ABHD6NPC1RAB9A | |
| SCHEMBL7854911 | 0.79 | ESR1 (0.70) | ESR1ESR2ABHD6ACACB | |
| SCHEMBL10312979 | 0.79 | HRH3 (0.67) | NPC1RAB9AKMT2AACACB | |
| SCHEMBL14677183 | 0.79 | ESR2 (0.59) | ESR1ESR2ABHD6NPC1RAB9A | |
| SCHEMBL14100712 | 0.79 | ESR2 (0.72) | ESR1ESR2ABHD6NPC1RAB9A | |
| SCHEMBL7847325 | 0.79 | ESR1 (0.85) | ESR1ESR2ABHD6HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| EP-1511727-B1 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20050261279-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| EP-1511727-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099786-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | SIGMAR1, CBR3, CBR1 | ESR1 312/4885ESR2 324/4885ABHD6 4171/4885 |
| US-20050261279-A1 | Compounds | CBR1, CBR3, OXER1 | ESR1 45/4885ESR2 54/4885ABHD6 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.